| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/500 - 1/2000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CAD; CPAN; DFF2; DFF40; DFF-40 |
| Entrez GeneID | 1677 |
| clone | 3F12D2 |
| WB Predicted band size | 39.1kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human DFFB (AA: 1-289) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇与DFFB抗体相关的研究文献摘要，供参考：
1. **文献名称**：*Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis*
**作者**：Enari, M. et al.
**摘要**：该研究首次报道了DFFB(CAD)在细胞凋亡中被caspase激活的机制。文中提及使用特异性抗体检测DFFB的活化形式，证实其与DNA断裂的直接关联。
2. **文献名称**：*Molecular cloning and characterization of human caspase-activated DNase*
**作者**：Liu, X. et al.
**摘要**：作者克隆了人源DFFB基因并制备了多克隆抗体，通过免疫印迹验证了DFFB在凋亡细胞中的蛋白水解过程，为后续功能研究提供工具。
3. **文献名称**：*Caspase-activated DNase/DNA fragmentation factor 40 mediates apoptotic nuclear fragmentation*
**作者**：Samejima, K. & Earnshaw, W.C.
**摘要**：研究利用DFFB特异性抗体进行免疫荧光定位，揭示了DFFB在凋亡过程中核小体间DNA切割的关键作用及亚细胞定位变化。
注：DFFB相关抗体研究多集中于1998-2000年其功能机制解析阶段，近年研究侧重其与疾病(如癌症、神经退行性疾病)的关联，建议结合具体应用场景补充检索近年文献。
The DNA Fragmentation Factor Beta (DFFB) antibody is a critical tool in studying apoptosis, a programmed cell death mechanism essential for maintaining cellular homeostasis. DFFB, also known as caspase-activated DNase (CAD), forms a heterodimer with its inhibitor DFFA (ICAD). During apoptosis, caspase-3 cleaves DFFA, releasing active DFFB to fragment nuclear DNA, a hallmark of apoptotic cell death. This process ensures efficient elimination of damaged or unnecessary cells, playing roles in development, immune regulation, and cancer suppression.
DFFB antibodies are widely used to detect DFFB expression and activation in research models, helping elucidate apoptotic pathways in diseases like cancer, neurodegeneration, and autoimmune disorders. They enable techniques such as Western blotting, immunohistochemistry, and flow cytometry to assess DFFB localization, cleavage status, and interaction partners. Commercial DFFB antibodies are typically raised against specific epitopes, with validation in knock-out controls to ensure specificity. Dysregulation of DFFB is linked to pathological conditions; for example, reduced DFFB activity may impair apoptosis, promoting tumor survival. Conversely, excessive DFFB activation could contribute to tissue damage in neurodegenerative diseases. Researchers also utilize these antibodies to screen therapeutic agents targeting apoptotic pathways or to diagnose diseases with apoptotic abnormalities.
×
